Booster Vaccination After Neonatal Priming with Acellular Pertussis Vaccine - 07/03/14
Abstract |
After a birth dose of acellular pertussis (aP) and diphtheria (DT)aP-hepatitis B virus (HBV)-inactivated polio vaccine (IPV)/Haemophilus influenza type b (Hib) at 2, 4, and 6 months, a booster dose of DTaP-HBV-IPV/Hib at 12 to 23 months induced strong anti-pertussis booster responses. Thus, neonatal aP priming did not lead to immune tolerance to pertussis antigens. However, it elicited bystander interference on HBV, Hib, and diphtheria responses.
Le texte complet de cet article est disponible en PDF.Mots-clés : aP, DT, FHA, GMC, GMT, HBs, HBP, Hib, IPV, PRP
Plan
Funded by GlaxoSmithKline Biologicals, Rixensart, Belgium (Study No. 105752). J.-M.J. and A.C. are employees of GlaxoSmithKline Biologicals. C.-A.S., H.-J.S., F.Z., and M.K. have received honoraria for participation to scientific advisory boards of GSK and other pharmaceutical companies, as well as research grants from pharmaceutical companies within the past 3 years. |
|
D.K. and C.U.M. declare no conflicts of interest. |
|
Registered at www.clinicaltrials.com (NCT00289796). |
Vol 156 - N° 4
P. 675-678 - avril 2010 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?